MS patients participating; Sanofi expects to submit the app to the FDA later this year. Sanofi, which owns Genzyme, manufacturer of the MS drugs
To match the price of other MS drugs, Genzyme/Sanofi-Aventis would need to This was intended to help the company optimise the price of the drug once approved
The Sanofi-Genzyme MS drug Lemtrada reduces relapse rate but doesn't improve disability in a two-year study.
Sanofi is a leader in MS. Sanofi Genzyme, the specialty care global business unit of Sanofi, currently has two marketed MS medicines available around the
As Sanofi/Genzyme plans to take leukemia drug Campath out of the Sanofi/Genzyme MS Drug Lemtrada Scores High Against Rebif. Pink
Rosalind Kalb, PhD – Consultant: Sanofi-Genzyme and Novartis Pharmaceuticals Treatment optimization in MS: Canadian MS Working Group.
Sanofi said its U.S. subsidiary Genzyme has received approval from the Food and Drug Administration for its multiple-sclerosis drug Lemtrada. sanofis-genzyme-gets-fda-approval-for-ms-drug
To match the price of other MS drugs, Genzyme/Sanofi-Aventis would need to find a way to differentiate the price of the drug between that intended for B-CLL and
Sanofi and Genzyme Report New Positive Data from First Phase III Study with MS Drug. Octo. In comparison with Rebif, alemtuzumab increased the
Comments
Always a living fan,
Santacruzman